Arvinas, Inc. (ARVN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arvinas, Inc. (ARVN) Healthcare & Pipeline Overview

Arvinas, Inc. pioneers PROTAC protein degraders, targeting diseases by eliminating disease-causing proteins, differentiating itself in the biotechnology sector through innovative drug development and strategic collaborations with pharmaceutical giants like Pfizer and Roche, while focusing on oncology and other therapeutic areas.

What Is the Investment Thesis for ARVN?

Arvinas, Inc. presents a notable research candidate within the biotechnology sector, driven by its innovative PROTAC technology and promising clinical pipeline. The company's lead candidates, including Bavdegalutamide and ARV-471, target significant unmet needs in prostate and breast cancer, respectively. Positive clinical trial data could serve as a major catalyst for stock appreciation. Strategic collaborations with Pfizer, Roche, and Bayer validate the potential of Arvinas's platform and provide financial stability. However, the company faces inherent risks associated with clinical-stage drug development, including regulatory hurdles and potential setbacks in clinical trials. With a market cap of $562M, Arvinas offers high-growth potential but also carries significant risk. Investors should closely monitor clinical trial results and regulatory developments.

Based on FMP financials and quantitative analysis

ARVN Key Highlights

Market capitalization of $562M reflects investor sentiment regarding the company's future potential in the biotechnology space.

• Gross margin of 99.5% indicates strong potential profitability upon commercialization of successful drug candidates.
• Profit margin of -30.8% is typical for a clinical-stage biopharmaceutical company heavily investing in research and development.
• Beta of 1.94 suggests higher volatility compared to the overall market, reflecting the speculative nature of biotechnology investments.
• Strategic collaborations with Pfizer, Genentech, Roche, and Bayer provide financial resources and validation of Arvinas's PROTAC technology.

Who Are ARVN's Competitors?

ARVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ARVN's Key Strengths?

Innovative PROTAC technology platform.

• Strong intellectual property position.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team.

What Are ARVN's Weaknesses?

Clinical-stage company with no currently marketed products.

• High research and development costs.
• Reliance on clinical trial outcomes and regulatory approvals.
• Negative profit margin.

What Could Drive ARVN Stock Higher?

Phase 1 clinical trial results for Bavdegalutamide in metastatic castration-resistant prostate cancer (mCRPC).

• Clinical trial data updates for ARV-471 in metastatic ER positive/HER2 negative breast cancer.
• Progress in strategic collaborations with Pfizer, Genentech, Roche, and Bayer.
• Expansion of the PROTAC platform to new therapeutic areas.
• Regulatory submissions and potential approvals for lead drug candidates.

What Are the Key Risks for ARVN?

Financial-distress signal — its Altman Z-Score of 1.37 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-44.4%) — the business is not currently generating profit on shareholder capital.
• Rich valuation — a P/E of 45.84 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Clinical trial failures or setbacks.
• Regulatory delays or rejections.
• Competition from other biotechnology and pharmaceutical companies.
• Patent challenges or intellectual property disputes.
• High research and development costs.

What Are the Growth Opportunities for ARVN?

• Expansion of PROTAC Platform: Arvinas has the opportunity to expand its PROTAC platform beyond oncology to address other therapeutic areas, such as neurodegenerative diseases and autoimmune disorders. The market for these therapies is substantial, with significant unmet needs. Successful development of PROTAC-based therapies in these areas could drive significant revenue growth. The timeline for this expansion depends on research and development progress, but initial clinical trials could begin within the next 3-5 years.
• Advancement of Bavdegalutamide: Bavdegalutamide, Arvinas's PROTAC protein degrader targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), represents a significant growth opportunity. Positive Phase 1 clinical trial results could lead to further development and eventual commercialization. The market for mCRPC therapies is substantial, with a growing need for more effective treatments. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory approvals, but could be within 5-7 years.
• Development of ARV-471: ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer, offers a significant growth opportunity. Positive clinical trial data could lead to further development and eventual commercialization. The market for breast cancer therapies is substantial, with a growing need for more effective treatments. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory approvals, but could be within 5-7 years.
• Strategic Partnerships: Arvinas can continue to leverage strategic partnerships with major pharmaceutical companies to accelerate the development and commercialization of its PROTAC-based therapies. These partnerships provide financial resources, expertise, and access to global markets. Expanding these collaborations could significantly enhance Arvinas's growth prospects. The timeline for new partnerships is uncertain, but ongoing discussions with potential partners are likely.
• Expansion of Pipeline: Arvinas has the opportunity to expand its pipeline of PROTAC-based therapies to address a wider range of diseases. This could involve developing new PROTACs targeting different disease-causing proteins or exploring new applications for existing PROTACs. A broader pipeline would reduce the company's reliance on its lead candidates and enhance its long-term growth potential. The timeline for pipeline expansion depends on research and development progress, but new candidates could enter clinical trials within the next 3-5 years.

What Are ARVN's Competitive Advantages?

• Proprietary PROTAC technology platform.
• Strong intellectual property portfolio protecting their drug candidates.
• Strategic collaborations with major pharmaceutical companies.
• First-mover advantage in the field of protein degradation therapies.
• Expertise in drug discovery and development.

What Does ARVN Do?

Founded in 2013 and based in New Haven, Connecticut, Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by developing novel protein degradation therapies. The company's core technology revolves around proteolysis-targeting chimeras (PROTACs), a revolutionary approach to drug development that aims to eliminate disease-causing proteins rather than just inhibiting them. This innovative strategy has the potential to address a wide range of diseases, including cancer and other therapeutic areas. Arvinas's lead product candidates include Bavdegalutamide, currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer (mCRPC). Bavdegalutamide targets the androgen receptor (AR) protein. ARV-471, another key candidate, is being developed for metastatic ER positive/HER2 negative breast cancer, targeting the estrogen receptor protein. ARV-766, an orally bioavailable PROTAC protein degrader, is also under investigation for mCRPC. Arvinas has established collaborations with major pharmaceutical companies, including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG, to further advance its research and development efforts and expand the potential applications of its PROTAC technology. These collaborations provide Arvinas with significant financial resources and expertise, accelerating the development and commercialization of its innovative therapies.

What Products and Services Does ARVN Offer?

• Develop proteolysis-targeting chimera (PROTAC) protein degraders.
• Target disease-causing proteins for degradation.
• Focus on therapies for cancer and other diseases.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Collaborate with pharmaceutical companies to advance research and development.
• Seek regulatory approvals for their therapies from agencies like the FDA.

How Does ARVN Make Money?

• Develop and patent novel PROTAC protein degraders.
• Conduct preclinical and clinical research to evaluate drug candidates.
• Partner with pharmaceutical companies for funding and expertise.
• Out-license or co-develop their therapies for commercialization.
• Generate revenue through milestone payments, royalties, and future product sales.

What Industry Does ARVN Operate In?

Arvinas operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence rates. Arvinas's PROTAC technology offers a novel approach to drug development, potentially disrupting traditional treatment paradigms. The company competes with established pharmaceutical companies and other biotechnology firms developing innovative cancer therapies. Success in this industry hinges on scientific innovation, clinical trial outcomes, and regulatory approvals.

Who Are ARVN's Key Customers?

• Patients suffering from cancer and other diseases.
• Pharmaceutical companies seeking innovative therapies.
• Healthcare providers who prescribe and administer treatments.
• Research institutions involved in clinical trials.
• Strategic partners collaborating on drug development.

Over the past six months, Arvinas, Inc. insiders filed 21 SEC Form 4 transactions — 9 sales and 12 purchases. On net that is roughly 169K shares acquired (about $508K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Arvinas, Inc.

Revenue for Arvinas, Inc. came in at $249.7M during Q2 FY2026, a 1500.6% improvement versus the preceding quarter. The company recorded net income of $169.4M, with diluted EPS of $2.58. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, ARVN averaged $0.04 in diluted EPS.

ARVN Valuation & Market Position

With a $562M market cap, Arvinas, Inc. sits in the small-cap segment of the market. Analyst price targets span from $10.00 to $20.00, with a consensus of $13.57. At the current price of $8.71, that implies approximately 56% upside potential. Relative to its peer group, ARVN's quantitative score of 41/100 is below the peer average of 83/100.

Return on equity for Arvinas, Inc. stands at -44.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -57.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -49.5%, the inverse of the P/E and a quick read on earnings relative to price.

Arvinas, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.37 places it in the distress zone, a signal of elevated financial risk.

Arvinas, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 128.8% above estimates on average.

Company Profile

Arvinas, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Randy Teel. ARVN has traded publicly since 2018.

ARVN Financials

ARVN Latest News

ARVN Analyst Consensus

ARVN MoonshotScore

Latest Arvinas, Inc. Analysis

What Investors Ask About Arvinas, Inc. (ARVN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources